× Industry Reports Services Press Release Contact us About us

Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Share By Test Type (Fecal Occult Blood Tests [Guaiac FOB Stool, Immuno-FOB Agglutination, Lateral Flow Immuno-FOB, Immuno-FOB ELISA], Biomarker Tests [Tumor M2-PK Stool, Transferrin Assays], CRC DNA Screening Tests [Methylated Gene Testing, Panel DNA Tests]) Industry Analysis Report, Regional Outlook (Japan, China, India, Australia, South Korea, Malaysia, Indonesia, Thailand, Singapore, Taiwan, Philippines, Vietnam), Application Potential, Competitive Market Share & Forecast, 2020 - 2026

Published Date: February 2020 | Publisher: Graphical Research Report ID: GR1303 | Delivery : PDF

Industry Trends

Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Value was valued over USD 150.0 million in 2019 and is expected to witness 6.5% CAGR from 2019 to 2026.

Get more details on this report - Request Free Sample PDF

The increasing incidences of CRC in the Japan, China, and India is expected to drive the market for CRC screening test. For instance, approximately 376.3 thousand new cases of colorectal cancer were recorded in 2015 in China. In 2012, around 430,000 primary screening and 33,000 colonoscopies were performed among 15 sites in China. The rising socio-economic disparities, rising geriatric population, changing food and life style, increased smoking habits and obesity contribute to the growth of colorectal cancer screening tests in the region.

Increasing government initiatives cancer and funding for the early detection of colorectal cancer propel the growth of the market in Asia Pacific region. The National Comprehensive Cancer Network (NCCN) had introduced guidelines for the treatment of colorectal cancer treatment that are widely accepted by oncologists. Also, initiatives like continuous medical education policy adopted by the government, with regular tours of specialists and training program of multidisciplinary team, developed surgical treatment of rectal cancer and strategy to solve problems will boost the invitro colorectal cancer screening market.

Asia Pacific Market Share, By Test Type

CRC DNA screening test segment will account the highest growth rate during the forecasting period growing at 10.6% CAGR in the Asia Pacific region. The increased demand for CRC DNA screening is due to improved accuracy. Also, the recognition of mutant DNA from shed tumor cells in the stool for colon cancer will improve the investigation accuracy. It also helps to guide and inform the physician for the best method for optimum patient treatment and outcome.

Asia Pacific Market Size, By Country

Japan in-vitro colorectal cancer screening tests market recorded approximately USD 52.0 million revenue size in 2019. The escalating number of colorectal cancer and the increasing geriatric population fuels the growth of the market in the country. Also, the increasing initiative taken by the government to screen the patients for cancer significantly drives the market. The Cancer Control Act 2006 has set a plan to promote Cancer Control Program, with aim to increase the uptake in each cancer screening program to 50%. Further, growing awareness towards reducing mortality and early detection, increasing demand for colorectal cancer screening by OC and FOBT with related interferences, rising funding for research project by Ministry of Health, Welfare and Labor, improvement in the colorectal cancer screening uptake will fuel the industry growth.

Competitive Market Share

Some of the major industry players involved in Asia Pacific in-vitro colorectal cancer screening tests market include Abbott Laboratories, Beckman Coulter Diagnostics, Eiken Chemical Co. Ltd., EMD Millipore, among other market players. The market for in-vitro colorectal cancer screening tests is highly fragmented with the firms focusing on rigourus expansion strategies to develop advanced tests capable of delivering accurate results instantly. For instance, in 2016, Siemens Healthineers announced the expansion of its manufacturing facility in China. This enables manufacturing operations for immunoassay reagents and clinical chemistry in the country.

Industry Background

The most recommended CRC screening tests are Faecal occult blood test (FOBT, immunochemical tests, and guaiac-based), colonoscopy and flexible sigmoidoscopy. CT colonography and barium enema are not recommended for CRC screening in Asia Pacific region. In many resource-limited countries, FOBT is the most preferred test for CRC screening. This is attributed to the low-cost and ease to use trends. However, the adoption of CRC DNA screening is also significantly on rise due to its efficiency and improved investigation accuracy. The incidence of colon and rectal cancer, growing longevity coupled with lifestyle changes such as lack of physical exercise and poor diet fuel the market growth in the forthcoming years.

Frequently Asked Question(FAQ) :

Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Value was valued over USD 150.0 million in 2019 and is expected to witness 6.5% CAGR from 2019 to 2026.
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Share By Test Type (Fecal Occult Blood Tests [Guaiac FOB Stool, Immuno-FOB Agglutination, Lateral Flow Immuno-FOB, Immuno-FOB ELISA], Biomarker Tests [Tumor M2-PK Stool, Transferrin Assays], CRC DNA Screening Tests [Methylated Gene Testing, Panel DNA Tests]) Industry Analysis Report, Regional Outlook (Japan, China, India, Australia, South Korea, Malaysia, Indonesia, Thailand.
Some of the major industry players involved in Asia Pacific in-vitro colorectal cancer screening tests market include Abbott Laboratories, Beckman Coulter Diagnostics, Eiken Chemical Co. Ltd., EMD Millipore, among other market players.

Select License

APAC In-vitro Colorectal Cancer Screening Tests Market Forecast (2020-2026)


Why Choose us?
  • On-Time Delivery
  • Assured Quality
  • Industry Experts
  • Payment Security
Share Social-media